Effects of calcitriol on type 5b tartrate-resistant acid phosphatase and interleukin-6 in secondary hyperparathyroidism

Blood Purification

Volumn 24, Issue 5-6, 2006, Pages 423-430

  Lu, Kuo Cheng ^a,b   Tseng, Chin Feng ^a   Wu, Chia Chao ^b   Yeung, Lai King ^a   Chen, Jin Shuen ^b   Chao, Tsu Yi ^b   Janckila, Anthony J ^c,d   Yam, Lung T ^c,d   Chu, Pauling ^b  

^a FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c University of Louisville School of Medicine   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alkaline phosphatase, bone specific; Calcitriol; Hyperparathyroidism, secondary; Interleukin 6; Tartrate resistant acid phosphatase

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCITRIOL; INTERLEUKIN 6; PARATHYROID GLAND HORMONE;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; BONE REMODELING; CLINICAL ARTICLE; DISEASE MARKER; DRUG EFFECT; FEMALE; HEMODIAFILTRATION; HUMAN; LOW DRUG DOSE; MALE; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACID PHOSPHATASE; AGED; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CALCITRIOL; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; INFLAMMATION; INTERLEUKIN-6; ISOENZYMES; MALE; MIDDLE AGED; PARATHYROID HORMONE; RENAL DIALYSIS; TIME FACTORS;

EID: 33845921650     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094899     Document Type: Article

References (29)

1. Hruska KA, Teitelbaum SL: Renal osteodystrophy. N Engl J Med 1995;333:166-174.
2. Termine J: Bone matrix proteins and the mineralization process; in Favus M (ed): Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. New York, Raven Press, 1993, pp 21-25.
3. de Vernejoul MC, Kuntz D, Miravet L, Gueris J, Bielakoff J, Ryckewaert A: Bone histomorphometry in hemodialysed patients. Metab Bone Dis Relat Res 1981;3:175-179.
4. Chu P, Chao TY, Lin YF, Janckila AJ, Yam LT: Correlation between histomorphometric parameters of bone resorption and serum type-5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis. Am J Kidney Dis 2003;41:1052-1059.
5. Anh D, Dimai H, Hall S, Farley J: Skeletal alkaline phosphatase activity is primarily released from human osteoblasts in an insoluble form and the net release is inhibited by calcium and skeletal growth factors. Calcif Tissue Int 1998;62:332-340.
6. Ureña P, Bernard-Poenaru O, Cohen-Solal M, de Vernejoul MC: Plasma bone-specific alkaline phosphatase changes in hemodialysis patients treated by alfacalcidol. Clin Nephrol 2002;57:261-273.
7. Peter S, Markus K, Richard JJ, Bengt L, Roberto PF, Miguel R, Olof H, Tommy C, Matthias G: IL-10, IL-6, and TNFα: central factors in the altered cytokine network of uremia - the good, the bad and the ugly. Kidney Int 2005;67:1216-1233.
8. Stenvinkel P, Barany P, Heimbürger O, Pecoits-Filho R, Lindholm B: Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6? Kidney Int 2002;61:103-108.
9. Safley SA, Villinger F, Jackson EH, Tucker-Burden C, Cohen C, Weber CJ: Interleukin-6 production and secretion by human parathyroids. Clin Exp Immunol 2004;136:145-156.
10. Jankila AJ, Takahashi K, Sun SZ, Yam LT: Tartrate resistant acid phosphatase isoform 5b was a serum marker for osteoblastic activity. Clin Chem 2001;47:74-80.
11. Takahashi N, Akatsu T, Udagawa N, Sasaki T, Yamaguchi A, Moseley JM, Martin TJ, Suda T: Osteoblastic cells are involved in osteoclast formation. Endocrinology 1998;123:2600-2602.
12. Parfitt AM: Bone-forming cells in clinical conditions; in Hall BK (ed): Bone, vol 1: The Osteoblast and Osteocyte. Boca Raton, CRC Press, 1990, pp 351-429.
13. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC: Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999;104:439-446.
14. Gonazlez E, Martin K: Coordinate regulation of PTH/PTHrP receptors by PTH and calcitriol in UMR 106-01 osteoblast-like cells. Kidney Int 1996;50:63-70.
15. 3 in fetal bone. Science 1977;197:1086-1088.
16. Yam LT: Clinical significance of human acid phosphatases. Am J Med 1974;56:604-616.
17. Stepan JJ, Silinkova-Malkova E, Havranek T, Formankova J, Zichova M, Lachmanova J, Strakova M, Broulik P, Pacovsky V: Relationship of plasma tartrate-resistant acid phosphatase to the bone isoenzyme of serum alkaline phosphatase in hyperparathyroidism. Clin Chim Acta 1983;133:189-200.
18. Shibata T, Shira-Ishi A, Sato T, Masaki T, Sasaki A, Masuda Y, Hishiya A, Ishikura N, Higashi S, Uchida Y, Saito M-O, Ito M, Ogata E, Watanabe E, Ikeda KY: Vitamin D hormone inhibits osteoclastogenesis in vivo by decreasing the pool of osteoclast precursors in bone marrow. J Bone Miner Res 2001;17:622-629.
19. Adebanjo OA, Moonga BS, Yamate T, et al: Mode of action of interleukin-6 on mature osteoclasts. J Cell Biol 1998;142:1347-1356.
20. Radeff JM, Nagy Z, Stern PH: Involvement of PKC-beta in PTH, TNF-alpha, and IL-1 beta effects on IL-6 promoter in osteoblastic cells and on PTH-stimulated bone resorption. Exp Cell Res 2001;268:179-188.
21. Sanders JL, Stern PH: Protein kinase C involvement in interleukin-6 production by parathyroid hormone and tumor necrosis factor-alpha in UMR-106 osteoblastic cells. J Bone Miner Res 2000;15:885-893.
22. Nagy Z, Radeff J, Stern PH: Stimulation of interleukin-6 promoter by parathyroid hormone, tumor necrosis factor alpha, and interleukin-1β in UMR-106 osteoblastic cells is inhibited by protein kinase C antagonists. J Bone Miner Res 2001;16:1220-1227.
23. Julie MR, Zsolt N, Paula HS: Rho and Rho kinase are involved in parathyroid hormone-stimulated protein kinase C translocation and IL-6 promoter activity in osteoblastic cells. J Bone Miner Res 2004;19:1882-1891.
24. Mitnick MA, Grey A, Masiukiewicz U, Bartkiewicz M, Rios-Velez L, Friedman S, Xu L, Horowitz MC, Insogna K: Parathyroid hormone induces hepatic production of bioactive interleukin-6 and its soluble receptor. Am J Physiol Endocrinol Metab 2001;280:E405-E412.
25. Borazan A, Ustun H, Cefle A, Sekitmez N, Yilmaz A: Comparative efficacy of oral and intravenous calcitriol treatment in haemodialysis patients: effects on serum biochemistry and cytokine levels. J Int Med Res 2003;31:489-496.
26. Simon JS, Christopher WM, Neil JS, Jacky MB, John C: Impaired release of interleukin-6 from human osteoblastic cells in the uraemic milieu. Nephrol Dial Transplant 2004;19:3078-3083.
27. McIntyre C, Schroeder NJ, Burrin J, Cunningham J: Effects of new analogues of vitamin D on bone cells: implications for treatment of uraemic bone disease. Kidney Int 1999;55:500-511.
28. Jaroszynski AJ, Ksiazek A: Changing relationships between serum IL-1, IL-6, and TNF-α and dynamic tests of parathyroid gland function in haemodialysis patients with severe hyperparathyroidism in response to calcitriol therapy. Nephrol Dial Transplant 2000;15:1718-1719.
29. Harada SI, Rodan GA: Control of osteoblast function and regulation of bone mass. Nature 2003;423:349-355.